Total Payments
$55,142
2024 Payments
$2,312
Companies
36
Transactions
248
Medicare Patients
1,900
Medicare Billing
$67,208
Payment Breakdown by Category
Other$17,020 (30.9%)
Consulting$16,589 (30.1%)
Travel$10,238 (18.6%)
Research$5,963 (10.8%)
Food & Beverage$5,246 (9.5%)
Education$85.58 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $17,020 | 8 | 30.9% |
| Consulting Fee | $16,589 | 8 | 30.1% |
| Travel and Lodging | $10,238 | 38 | 18.6% |
| Unspecified | $5,963 | 10 | 10.8% |
| Food and Beverage | $5,246 | 179 | 9.5% |
| Education | $85.58 | 5 | 0.2% |
Payments by Type
General
$49,179
238 transactions
Research
$5,963
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ARBOR PHARMACEUTICALS, INC. | $23,332 | 49 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $13,901 | 24 | $0 (2019) |
| ARALEZ PHARMACEUTICALS US INC. | $9,774 | 29 | $0 (2018) |
| Abbott Laboratories | $1,514 | 14 | $0 (2024) |
| CVRx, Inc. | $1,392 | 8 | $0 (2024) |
| Theravance Biopharma Inc. | $1,219 | 3 | $0 (2017) |
| GlaxoSmithKline, LLC. | $1,161 | 8 | $0 (2017) |
| Amgen Inc. | $468.30 | 24 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $449.41 | 9 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $368.81 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,312 | 25 | CVRx, Inc. ($1,392) |
| 2022 | $51.36 | 2 | Gilead Sciences, Inc. ($34.37) |
| 2021 | $79.79 | 5 | Boehringer Ingelheim Pharmaceuticals, Inc. ($34.67) |
| 2020 | $56.01 | 3 | Abbott Laboratories ($24.62) |
| 2019 | $6,808 | 41 | Novartis Pharmaceuticals Corporation ($4,727) |
| 2018 | $693.80 | 40 | Amgen Inc. ($224.09) |
| 2017 | $45,141 | 132 | Arbor Pharmaceuticals, Inc. ($23,166) |
All Payment Transactions
248 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $28.69 | General |
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $74.06 | General |
| 10/30/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: Diabetes | ||||||
| 10/19/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $76.20 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $44.91 | General |
| Category: Cardiology | ||||||
| 09/17/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $21.02 | General |
| Category: Obesity | ||||||
| 09/11/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $53.91 | General |
| Category: Heart Failure | ||||||
| 09/11/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Education | In-kind items and services | $27.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/10/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $81.57 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/27/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: Heart Failure | ||||||
| 08/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $121.16 | General |
| Category: Cardio-renal | ||||||
| 08/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: DIABETES | ||||||
| 07/18/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $45.87 | General |
| 07/09/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: Heart Failure | ||||||
| 06/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $121.71 | General |
| Category: DIABETES | ||||||
| 05/31/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SYNJARDY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: DIABETES | ||||||
| 05/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $97.97 | General |
| Category: Heart Failure and Hypertension | ||||||
| 05/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $76.07 | General |
| Category: Heart Failure and Hypertension | ||||||
| 05/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $65.63 | General |
| Category: Heart Failure and Hypertension | ||||||
| 05/03/2024 | CVRx, Inc. | Barostim Neo System (Device) | Travel and Lodging | Cash or cash equivalent | $466.34 | General |
| Category: Heart Failure and Hypertension | ||||||
| 05/03/2024 | CVRx, Inc. | Barostim Neo System (Device) | Travel and Lodging | Cash or cash equivalent | $443.70 | General |
| Category: Heart Failure and Hypertension | ||||||
| 05/03/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $172.21 | General |
| Category: Heart Failure and Hypertension | ||||||
| 03/19/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $117.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/08/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $21.96 | General |
| Category: Heart Failure and Hypertension | ||||||
| 01/24/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $47.78 | General |
| Category: Heart Failure and Hypertension | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $4,713 | 1 |
| A Phase IIb, 24 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of two doses of umeclidinium bromide administered once daily via a dry powder inhaler, versus placebo, in participants with asthma | GlaxoSmithKline, LLC. | $1,161 | 8 |
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $89.56 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 10 | 515 | 569 | $85,334 | $31,335 |
| 2020 | 12 | 1,385 | 1,702 | $186,717 | $35,872 |
Total Patients
1,900
Total Services
2,271
Medicare Billing
$67,208
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 114 | 146 | $21,330 | $13,636 | 63.9% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 66 | 67 | $20,345 | $5,071 | 24.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 36 | 36 | $9,003 | $4,290 | 47.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 47 | 54 | $5,385 | $3,712 | 68.9% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2021 | 24 | 24 | $12,395 | $1,327 | 10.7% |
| 93925 | Ultrasound study of arteries and arterial grafts of both legs | Office | 2021 | 18 | 18 | $4,437 | $819.58 | 18.5% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 110 | 123 | $5,525 | $819.05 | 14.8% |
| 93880 | Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck | Office | 2021 | 16 | 16 | $1,984 | $609.50 | 30.7% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 55 | 55 | $3,281 | $581.60 | 17.7% |
| 93923 | Ultrasound study of arteries of both arms and legs, complete | Office | 2021 | 18 | 18 | $1,457 | $433.08 | 29.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 11 | 12 | $192.00 | $36.00 | 18.8% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2020 | 199 | 201 | $68,022 | $11,353 | 16.7% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 630 | 891 | $45,494 | $6,033 | 13.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 44 | 65 | $11,187 | $3,831 | 34.2% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 246 | 261 | $22,282 | $3,460 | 15.5% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2020 | 47 | 47 | $10,096 | $2,943 | 29.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 24 | 24 | $7,699 | $2,693 | 35.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 48 | 64 | $9,000 | $2,563 | 28.5% |
| 93880 | Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck | Office | 2020 | 36 | 36 | $3,600 | $1,133 | 31.5% |
| 93925 | Ultrasound study of arteries and arterial grafts of both legs | Office | 2020 | 17 | 17 | $4,237 | $833.96 | 19.7% |
| 93308 | Follow-up or limited ultrasound examination of heart | Facility | 2020 | 25 | 26 | $2,324 | $529.20 | 22.8% |
| 93923 | Ultrasound study of arteries of both arms and legs | Office | 2020 | 14 | 14 | $700.00 | $244.37 | 34.9% |
| 93321 | Follow-up or limited heart doppler ultrasound study of heart blood flow, valves, and chambers | Facility | 2020 | 19 | 20 | $721.00 | $115.56 | 16.0% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Office | 2020 | 11 | 11 | $561.66 | $76.83 | 13.7% |
| 93325 | Doppler ultrasound study of color-directed heart blood flow, rate, and valve function | Facility | 2020 | 25 | 25 | $794.00 | $62.91 | 7.9% |
About Dr. David Smith, MD
Dr. David Smith, MD is a Internal Medicine healthcare provider based in Winston Salem, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780780031.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Smith, MD has received a total of $55,142 in payments from pharmaceutical and medical device companies, with $2,312 received in 2024. These payments were reported across 248 transactions from 36 companies. The most common payment nature is "Honoraria" ($17,020).
As a Medicare-enrolled provider, Smith has provided services to 1,900 Medicare beneficiaries, totaling 2,271 services with total Medicare billing of $67,208. Data is available for 2 years (2020–2021), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Psychiatry
- Location Winston Salem, NC
- Active Since 09/15/2006
- Last Updated 07/10/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1780780031
Products in Payments
- Bidil (Drug) $22,546
- ENTRESTO (Drug) $13,901
- YOSPRALA (Drug) $9,655
- Confirm Rx (Device) $1,412
- Barostim Neo System (Device) $1,392
- VERAMYST (Drug) $1,161
- Triptodur (Drug) $701.50
- JARDIANCE (Drug) $316.51
- Corlanor (Drug) $226.41
- Repatha (Biological) $176.02
- XARELTO (Drug) $168.29
- NORTHERA (Drug) $160.56
- FARXIGA (Drug) $154.66
- OPSUMIT MACITENTAN (Drug) $141.97
- Kerendia (Drug) $121.16
- ZONTIVITY (Drug) $119.00
- WAINUA (Drug) $108.57
- Adempas (Drug) $104.91
- CARDIOMEMS (Device) $94.48
- Fluticasone Propionate and Salmeterol (Drug) $89.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Winston Salem
Dr. Hassan Alhosaini, M.d, M.D
Internal Medicine — Payments: $322,339
Internal Medicine $322,339
Jamy Ard, Md, MD
Internal Medicine — Payments: $272,273
Internal Medicine $272,273
Dr. Katharine Batt, M.d., Msc, M.D., MSC
Internal Medicine — Payments: $207,180
Internal Medicine $207,180
Mr. James Dugan, Md, MD
Internal Medicine — Payments: $165,584
Internal Medicine $165,584
Suman Wasan, Md, MD
Internal Medicine — Payments: $89,012
Internal Medicine $89,012
Dr. Mahesh Chandrasekhar, M.d, M.D
Internal Medicine — Payments: $59,424
Internal Medicine $59,424